

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Richard Hopkins
Date of last notice	11 August 2020
Date that director ceased to be director	15 May 2021

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
i. Vanhop Pty Ltd <Vanhop Super Fund A/C> - Director and beneficiary	i. 1,700,000 ordinary shares i. 3,125,000 Class A performance rights i. 3,125,000 Class B performance rights
ii. Mr Richard Miles Hopkins & Ms Maya Maureen vanden Dreisen <Jesam A/C> - Beneficiary	ii. 3,125,000 Class A performance rights ii. 3,125,000 Class B performance rights ii. 5,000,000 unlisted options with an exercise price of \$0.10 each, vesting immediately and expire on 19

+ See chapter 19 for defined terms.

Appendix 3Z
Final Director's Interest Notice

	<p>February 2022</p> <p>ii. 5,000,000 unlisted options with an exercise price of \$0.15 each, subject to vesting conditions vesting on 16 October 2019 and expire on 19 February 2022</p> <p>ii. 5,000,000 unlisted options with an exercise price of \$0.20 each, subject to vesting conditions vesting on 16 October 2019 and expire on 19 February 2022</p> <p>ii. 5,000,000 unlisted options with an exercise price of \$0.28 each, vesting on 16 October 2020 and expire on 19 February 2022</p> <p>ii. 5,000,000 unlisted options with an exercise price of \$0.30 each, vesting on 16 October 2020 and expire on 19 February 2022</p>
--	--

Part 3 – Director's interests in contracts

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.